Antag Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for obesity and cardiometabolic diseases via antagonism of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR). Its lead program, AT-7687, is a novel once-weekly subcutaneous peptide GIPR antagonist designed for co-administration with GLP-1 medicines and as a single-agent maintenance therapy. In non-human primate studies AT-7687 plus a GLP-1 produced best-in-industry weight loss and also improved glycemic control and lipid profiles independent of weight changes, reportedly without gastrointestinal side effects. The company plans to use the Series A proceeds to support clinical development of AT-7687 and to accelerate expansion of its pipeline of monthly injectable therapies and combinations beyond GLP-1 receptor agonists. The U.S. Food and Drug Administration has accepted Antag’s IND for AT-7687, setting the stage for clinical development to begin early next year. Alexander Hovard Sparre-Ulrich serves as CEO.

Total raised

$93M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2024